The Gene Expression Patterns in the Peripheral White Blood Cells of Type 2 Diabetic Patients

The Gene Expression Patterns in the Peripheral White Blood Cells of Type 2 Diabetic Patients, Special Relevance to Atherosclerosis

The investigators hypothesize that macrophages play a crucial role in the pathogenesis of atherosclerosis in patients with type 2 diabetes mellitus (T2DM).

Study Overview

• Status: Unknown
• Conditions: Diabetes Mellitus, Type 2; Atherosclerosis

Detailed Description

Cardiovascular events are the leading cause of death in developed countries worldwide, including Taiwan. Type 2 diabetes mellitus (T2DM), previously considered merely as one of the risk factors, has been recently unanimously accepted to be coronary artery disease-equivalent. How T2DM may lead to accelerated atherosclerosis remains obscure.

Hyperglycemia with or without hyperinsulinemia may lead to higher oxidative stress and generalized inflammation. The oxidative stress and inflammation may play a significant role in the pathogenesis in diabetic complications, including micro- and macro-vascular complications. Macrophages together with T-lymphocytes are the earliest cell-types found in fatty-streaks, the earliest atherosclerotic lesions. Macrophages are also well known cellular mediators of oxidative stress and inflammation. Therefore, it is plausible to hypothesize that macrophages play a crucial role in the pathogenesis of atherosclerosis in patients with T2DM. In addition, the other cell types of the peripheral white blood cells (WBC), such as neutrophils, have been shown to be intimately related to acute coronary syndrome. Therefore, the study on the biology of peripheral WBCs may tell us something about the pathophysiology of diabetic macro-vascular complications.

Methods:

1. Normal control: fasting plasma glucose (FPG) less than 126 mg/dl.

2. T2DM: FPG >＝126 mg/dl.

   • Group 1 (good glycemic control): hemoglobin A1c (HbA1c) <＝ 7% in the past 6 months
   • Group 2 (poor glycemic control): HbA1c >＝ 8% in the past 6 months
3. Blood sample will be collected at baseline and after aggressive control.

• Study Type: Observational
• Enrollment: 100

Contacts and Locations

Study Locations

• Taiwan
  • Taipei, Taiwan, 10012
    • Recruiting
    • National Taiwan University Hospital
    • Contact: Wei-Shiung Yang, MD, PhD; Phone Number: 7258 886-2-23123456; Email: wsyang@ha.mc.ntu.edu.tw

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 25 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Normal control: fasting plasma glucose (FPG) less than 126 mg/dl.

• T2DM: FPG >＝126 mg/dl.

  • Group 1 (good glycemic control): HbA1c<＝7% in the past 6 months
  • Group 2 (poor glycemic control): HbA1c>＝8% in the past 6 months

Exclusion Criteria:

• Acute systemic diseases

Study Plan

How is the study designed?

Collaborators and Investigators

• Sponsor: National Taiwan University Hospital
• Investigators: Principal Investigator: Wei-Shiung Yang, MD, PhD, National Taiwan University Hospital

Study record dates

Study Major Dates

• Study Start: November 1, 2003

Study Registration Dates

• First Submitted: September 9, 2005
• First Submitted That Met QC Criteria: September 9, 2005
• First Posted (Estimate): September 12, 2005

Study Record Updates

• Last Update Posted (Estimate): December 14, 2006
• Last Update Submitted That Met QC Criteria: December 13, 2006
• Last Verified: September 1, 2005

More Information

Terms related to this study

• Keywords: Diabetes mellitus; Gene expression; Monocyte; Monocyte gene expression
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Atherosclerosis
• Other Study ID Numbers: 9261700953